All Updates

All Updates

icon
Filter
Funding
Bionano Genomics raises USD 10 million via direct offering for working capital and general corporate purposes
Precision Medicine
Jul 5, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jul 5, 2024

Bionano Genomics raises USD 10 million via direct offering for working capital and general corporate purposes

Funding

  • Bionano Genomics has secured USD 10 million in a direct offering under definitive agreements with certain healthcare-focused institutional investors. The transaction includes the sale of ~17.5 million shares of common stock at an offering price of USD 0.57 per share. In a concurrent private placement, the company has agreed to issue unregistered clinical milestone-linked Series A and Series B warrants, each for the purchase of ~17.5 million shares of common stock at USD 0.57 per share. The offering is expected to be closed on July 8, 2024, subject to meeting closing conditions.

  • The company plans to use the funds for various corporate purposes such as improving working capital, funding R&D initiatives, paying off existing debts, and undertaking capital expenditures. 

  • Analyst Quicktake: In May 2024 , Bionano Genomics raised USD 18 million through a private placement of senior secured convertible debentures, due in May 2026. The funds were intended to retire the convertible debt financing that was first entered in October 2023 and later amended in February 2024.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.